Rhythm Pharmaceuticals (RYTM) Competitors $56.07 -1.67 (-2.89%) Closing price 04:00 PM EasternExtended Trading$54.74 -1.33 (-2.37%) As of 04:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends RYTM vs. ITCI, VTRS, MRNA, RDY, PCVX, SRPT, QGEN, ASND, ROIV, and RVMDShould you be buying Rhythm Pharmaceuticals stock or one of its competitors? The main competitors of Rhythm Pharmaceuticals include Intra-Cellular Therapies (ITCI), Viatris (VTRS), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Vaxcyte (PCVX), Sarepta Therapeutics (SRPT), Qiagen (QGEN), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry. Rhythm Pharmaceuticals vs. Intra-Cellular Therapies Viatris Moderna Dr. Reddy's Laboratories Vaxcyte Sarepta Therapeutics Qiagen Ascendis Pharma A/S Roivant Sciences Revolution Medicines Intra-Cellular Therapies (NASDAQ:ITCI) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, community ranking, dividends, profitability, valuation, media sentiment and analyst recommendations. Which has more risk and volatility, ITCI or RYTM? Intra-Cellular Therapies has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 2.14, indicating that its stock price is 114% more volatile than the S&P 500. Do institutionals & insiders have more ownership in ITCI or RYTM? 92.3% of Intra-Cellular Therapies shares are owned by institutional investors. 2.6% of Intra-Cellular Therapies shares are owned by insiders. Comparatively, 5.6% of Rhythm Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media favor ITCI or RYTM? In the previous week, Rhythm Pharmaceuticals had 4 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 17 mentions for Rhythm Pharmaceuticals and 13 mentions for Intra-Cellular Therapies. Intra-Cellular Therapies' average media sentiment score of 0.45 beat Rhythm Pharmaceuticals' score of 0.24 indicating that Intra-Cellular Therapies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intra-Cellular Therapies 6 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rhythm Pharmaceuticals 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend ITCI or RYTM? Intra-Cellular Therapies presently has a consensus target price of $103.62, indicating a potential downside of 19.44%. Rhythm Pharmaceuticals has a consensus target price of $68.09, indicating a potential upside of 18.63%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Rhythm Pharmaceuticals is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intra-Cellular Therapies 0 Sell rating(s) 8 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.53Rhythm Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.91 Is ITCI or RYTM more profitable? Intra-Cellular Therapies has a net margin of -14.07% compared to Rhythm Pharmaceuticals' net margin of -230.07%. Intra-Cellular Therapies' return on equity of -9.93% beat Rhythm Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Intra-Cellular Therapies-14.07% -9.93% -8.38% Rhythm Pharmaceuticals -230.07%-367.36%-77.47% Which has higher earnings & valuation, ITCI or RYTM? Intra-Cellular Therapies has higher revenue and earnings than Rhythm Pharmaceuticals. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Rhythm Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntra-Cellular Therapies$464.37M29.45-$139.67M-$0.87-147.83Rhythm Pharmaceuticals$77.43M45.56-$184.68M-$4.33-13.26 Does the MarketBeat Community believe in ITCI or RYTM? Intra-Cellular Therapies received 225 more outperform votes than Rhythm Pharmaceuticals when rated by MarketBeat users. However, 67.19% of users gave Rhythm Pharmaceuticals an outperform vote while only 67.01% of users gave Intra-Cellular Therapies an outperform vote. CompanyUnderperformOutperformIntra-Cellular TherapiesOutperform Votes52267.01% Underperform Votes25732.99% Rhythm PharmaceuticalsOutperform Votes29767.19% Underperform Votes14532.81% SummaryIntra-Cellular Therapies beats Rhythm Pharmaceuticals on 10 of the 19 factors compared between the two stocks. Get Rhythm Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RYTM vs. The Competition Export to ExcelMetricRhythm PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.53B$7.09B$5.82B$9.06BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-13.256.0726.1619.03Price / Sales45.56320.22455.9477.31Price / CashN/A67.8344.0437.47Price / Book20.006.827.704.73Net Income-$184.68M$138.11M$3.18B$245.69M7 Day Performance1.25%-1.02%-1.02%-1.33%1 Month Performance-0.22%-0.54%1.10%-1.00%1 Year Performance17.59%-2.43%18.06%15.52% Rhythm Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RYTMRhythm Pharmaceuticals4.097 of 5 stars$56.07-2.9%$68.09+21.4%+17.6%$3.45B$77.43M-12.95140Analyst ForecastInsider TradeNews CoverageITCIIntra-Cellular Therapies3.9215 of 5 stars$127.82-0.2%$103.62-18.9%+74.4%$13.59B$464.37M-146.92560Earnings ReportAnalyst ForecastNews CoverageVTRSViatris2.3367 of 5 stars$10.80flat$13.67+26.5%-16.5%$12.89B$15.43B-14.5938,000News CoverageMRNAModerna4.7473 of 5 stars$32.99+3.4%$66.89+102.8%-61.2%$12.70B$6.85B-5.675,600Analyst DowngradeOptions VolumeHigh Trading VolumeRDYDr. Reddy's Laboratories2.8963 of 5 stars$13.60-2.8%$17.00+25.0%-11.7%$11.35B$311.31B21.6527,048Gap DownPCVXVaxcyte2.6035 of 5 stars$84.00+0.2%$127.71+52.0%+11.3%$10.47BN/A-18.26160Insider TradePositive NewsSRPTSarepta Therapeutics4.5135 of 5 stars$107.95-1.4%$176.77+63.8%-20.4%$10.31B$1.24B86.361,314Upcoming EarningsQGENQiagen4.4462 of 5 stars$39.85-0.5%$48.78+22.4%-7.3%$8.84B$1.98B110.975,967Analyst DowngradeASNDAscendis Pharma A/S3.0265 of 5 stars$144.08+1.1%$193.43+34.3%-1.4%$8.74B$288.08M-17.83640Analyst ForecastROIVRoivant Sciences2.7495 of 5 stars$10.56+1.1%$18.08+71.2%-7.1%$7.69B$122.59M1.87860Insider TradeRVMDRevolution Medicines4.5192 of 5 stars$40.67-1.6%$66.25+62.9%+44.9%$6.84B$11.58M-11.33250 Related Companies and Tools Related Companies Intra-Cellular Therapies Competitors Viatris Competitors Moderna Competitors Dr. Reddy's Laboratories Competitors Vaxcyte Competitors Sarepta Therapeutics Competitors Qiagen Competitors Ascendis Pharma A/S Competitors Roivant Sciences Competitors Revolution Medicines Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RYTM) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rhythm Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
